Wednesday, July 8, 2026

Patent intelligence · US

US 11759506

AADC polynucleotides for the treatment of Parkinson's disease

granted A61KA61K35/761A61K38/51A61K48/005
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 17
Applicant portfolio 31
Patent details — US 11759506
Jurisdiction
US
Status
granted
Grant date
Sep 19, 2023
Expiration
Sep 14, 2043
Claims
18
CPC classes
A61K, A61K35/761, A61K38/51, A61K48/005
View on Google Patents ↗

Quick answer

US 11759506 (AADC polynucleotides for the treatment of Parkinson's disease) is held by VOYAGER THERAPEUTICS, INC.. Status: granted. Granted Sep 19, 2023. Expires Sep 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
18
CPC classes
A61K, A61K35/761, A61K38/51, A61K48/005, A61K48/0066, A61K48/0075

More from VOYAGER THERAPEUTICS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12419969

    AAV capsid variants and uses thereof

    VOYAGER THERAPEUTICS, INC. · Expires Sep 18, 2045

    granted
  2. US 12319929

    Compositions and methods for the treatment of Parkinson's disease

    VOYAGER THERAPEUTICS, INC. · Expires May 29, 2045

    granted
  3. US 12305189

    Compositions and methods for delivery of AAV

    VOYAGER THERAPEUTICS, INC. · Expires May 15, 2045

    granted
  4. US 12296025

    AAV capsid variants and uses thereof

    VOYAGER THERAPEUTICS, INC. · Expires May 8, 2045

    granted
  5. US 12291565

    Tau binding compounds

    VOYAGER THERAPEUTICS, INC. · Expires May 1, 2045

    granted
  6. US 12281321

    Frataxin expression constructs having engineered promoters and methods of use thereof

    VOYAGER THERAPEUTICS, INC. · Expires Apr 17, 2045

    granted
  7. US 12252703

    Closed-ended linear duplex DNA for non-viral gene transfer

    VOYAGER THERAPEUTICS, INC. · Expires Mar 13, 2045

    granted
  8. US 12146150

    Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery

    VOYAGER THERAPEUTICS, INC. · Expires Nov 14, 2044

    granted

Frequently asked questions

What is US patent 11759506?

US 11759506 (AADC polynucleotides for the treatment of Parkinson's disease) is held by VOYAGER THERAPEUTICS, INC.. Status: granted. Granted Sep 19, 2023. Expires Sep 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11759506?

VOYAGER THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 31 pharmaceutical patents for this assignee.

When does US 11759506 expire?

Our index shows an expiration date of Sep 14, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.